SC
BIOA

Steven Cohen’s BioAge Labs BIOA Stock Holding History

Steven Cohen’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,180
Closed -$545K – 4643
2025
Q4 		$545K Buy
+41,180
New +$365K ﹤0.01% 3191
2024
Q4 		– Sell
-2,700
Closed -$56.2K – 2536
2024
Q3 		$56.2K Buy
+2,700
New +$54.1K ﹤0.01% 1896

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Steven Cohen's BIOA Position: Q1 2026 in Review

Steven Cohen sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 41,180 shares — an estimated $545K sold.

Steven Cohen first reported a position in BIOA in Q3 2024 and held it in 2 quarters. The position peaked at $545K in Q4 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Steven Cohen reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 41,180 BioAge Labs shares in Q1 2026, an estimated $545K.
  • Steven Cohen first reported a position in BioAge Labs in Q3 2024 and held it in 2 quarters.
  • Steven Cohen's BioAge Labs position peaked at $545K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.